Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies

1 Jan 2015

Abstract excerpt

DNA of 258 patients with treatment-resistant depression was collected in three 8-10 week, two-arm, prospective clinical trials. Forty-four allelic variations were measured in genes for the cytochrome P450 (CYP) enzymes CYP2D6, CYPC19, and CYP1A2, the serotonin transporter (SLC6A4), and the 5-HT2A receptor (HTR2A). The combinatorial pharmacogenomic (CPGx™) GeneSight test results were provided to clinicians to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Treatment of Major Depression
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27606312
DOI: 10.1159/000430915

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical StudiesPMID 27606312Read ↗

A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.Semantic proximity Read ↗

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.Semantic proximity Read ↗

Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive DisorderSemantic proximity Read ↗

Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.Semantic proximity Read ↗

Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.Semantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responsesSemantic proximity Read ↗

Study protocol for an observational trial: Investigating pharmacogenetic impact on depression treatment using various sequencing and array methods (PharmGen-TRD Study)Semantic proximity Read ↗

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.Semantic proximity Read ↗

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.Semantic proximity Read ↗

Depression and Pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.